Global Recombinant Cell Culture Supplements Market to Reach $1.18 Billion by 2032 at a CAGR of 12.2%
06 Sep 2022
Gene TherapyAntibodyVaccineImmunotherapyAcquisition
DUBLIN, Sept. 6, 2022 /PRNewswire/ -- The "Global Recombinant Cell Culture Supplements Market: Focus on Pricing Analysis, Product, Application, Expression System, and Region - Analysis and Forecast, 2022-2032" report has been added to
ResearchAndMarkets.com's offering.
The global recombinant cell culture supplements market was estimated at $308.6 million in 2021 and is expected to reach $1,188.6 million by 2032, growing at a CAGR value of 12.24% during the forecast period 2022-2032. The growth in the global recombinant cell culture supplements market is expected to be driven by the rising demand for cell culture supplements, increasing investment in life sciences research and development, as well as growing advantages of recombinant supplements over traditional animal-derived supplements.
Market Lifecycle Stage
The global recombinant cell culture market is increasing at a rapid pace. The growing need for animal-free supplements in cell culture applications is aiding the growth of the recombinant cell culture supplements market. Recombinant cell culture supplements play a crucial role in enhancing cell viability, maintaining a healthy culture, and customizing the cell culture in accordance with the needs of the individual.
Increasing demand for immunotherapy and stem cell and regenerative medicine research is one of the major opportunities in the recombinant cell culture supplements market. Several cell culture companies, and biopharmaceutical companies are working collaboratively on drug development and using recombinant cell culture supplements as a therapeutic means for applications in biological drugs. Furthermore, the market witnessed major mergers and acquisitions in the past four years. For instance, recently, in March 2022, Thermo Fisher Scientific Inc. acquired PeproTech, Inc., a company that specializes in the development and manufacturing of recombinant proteins, in a deal of $1.85 billion.
Impact
Many biopharmaceutical products are being developed by utilizing the cell culture technique. The study of cell physiology and biochemistry is made possible through laboratory cell culture, which also opens up research avenues that are challenging to pursue in vivo. Controlling variables such as the culture media, culture conditions, population density, and growth rate makes it simple to assess the effects of medications or other substances on cultured cells.
Additionally, it allows analyzing the function of various genes and offers enormous potential in the field of genetics. It enables the assessment of harmful and carcinogenic chemicals on cells in the fields of oncology and virology and the comprehension of how different medications, viruses, and physical or chemical carcinogens interact.
Furthermore, the recombinant cell culture has various applications, such as research on vaccines, stem cells, gene therapy, and genetic engineering, as well as the creation of protein therapies manufacturing of genetically edited proteins such as monoclonal antibodies, insulin, and hormones.
Market Dynamics
Market Drivers
Increasing Demand for Recombinant Cell Culture Supplements Due to their Advantages
Increased Funding and Investment in Research and Development for Biopharmaceutical Products in Life Sciences Sector
Growing Number of Mergers and Acquisitions for Expanding Recombinant Cell Culture Supplements Portfolio
Push from Regulatory Bodies to Utilize Animal-Free Media Supplements in Cell Culture Process
Market Restraints
Challenging Manufacturing Process of Recombinant Proteins
Technical Complexities Associated with Recombinant Cell Culture Supplements
Market Opportunities
Increasing Need for Immunotherapies and Stem Cell and Regenerative Medicines
Increasing Preference for Serum-Free Media
Market Segmentation
by Product
Recombinant Albumin (rAlbumin)
Recombinant Epidermal Growth Factor (rEGF)
Recombinant Interleukin Growth Factor (rILGF)
Recombinant Transferrin (rTransferrin)
Recombinant Trypsin (rTrypsin)
Recombinant Insulin-like Growth Factor (rIGF)
Recombinant Stem Cell Factor (rSCF)
Recombinant Lysozyme (rLysozyme)
Others
by Application
Academic and Research Application
by Expression System
Mammalian
Yeast
Others
by Region
North America
Europe
Asia-Pacific
Latin America
Rest-of-the-World
Demand - Drivers and Limitations
Following are the demand drivers for the global recombinant cell culture supplements market:
Increasing Demand for Recombinant Cell Culture Supplements Due to their Advantages
Increased Funding and Investment in Research and Development for Biopharmaceutical Products in Life Sciences Sector
Growing Number of Mergers and Acquisitions for Expanding Recombinant Cell Culture Supplements Portfolio
Push from Regulatory Bodies to Utilize Animal-Free Media Supplements in Cell Culture Process
The market is expected to face some limitations too due to the following challenges:
Challenging Manufacturing Process of Recombinant Proteins
Technical Complexities Associated with Recombinant Cell Culture Supplements
Key Topics Covered:
1 Market Overview
2 Product, $ Mn, 2021-2032
3 Application, $Mn, 2021-2032
4 Expression System, $Mn, 2021-2032
5 Region, $Mn, 2021-2032
6 Competitive Landscape
Companies Mentioned
Merck KGaA
For more information about this report visit https://www.researchandmarkets.com/r/jqnhuv
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.